VRDN
Viridian Therapeutics, Inc.\DE
NASDAQ · Healthcare · Biotechnology · US
$20.80
+9.30%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$19.23
From 52W high−38.43%
Volume2.58M
Market cap$2.36B
P/E (TTM)—
P/S (TTM)33.1x
Div yield—
Key dataOct 19, 2026
Open
$19.23
From 52W high
−38.43%
Volume
2.58M
Market cap
$2.36B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.7x
P/E (TTM)
—
RSI (14)
53.6
MomentumView details →
1D Return
+9.30%
YTD Return
−34.22%
SummaryUpdated Jun 1, 2026
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a clinical-stage biotechnology company founded in 2006 and headquartered in Waltham, Massachusetts. Originally established as Miragen Therapeutics, the company underwent a strategic transformation and rebranded to Viridian Therapeutics in January 2021. The company has evolved from its initial focus on microRNA-based therapeutics to become a specialized developer of antibody treatments targeting serious autoimmune and rare diseases, with particular emphasis on thyroid eye disease.
Similar companies
Latest newsMore news →
Viridian Therapeutics reported its Q2 2026 financial results, with total revenues of $284,000 and a net loss of $127.1 million.75d agoViridian Therapeutics received early FDA approval for Lumvoa, a treatment for thyroid eye disease.111d agoThe U.S. FDA approved Lumvoa (veligrotug-vvze) developed by Viridian Therapeutics for the treatment of thyroid eye disease.115d ago